PY8119 Xenograft Model Service for Breast Cancer

The PY8119 xenograft model offers an advanced, highly metastatic in vivo translational platform specifically optimized for evaluating novel immunotherapies, targeted agents, and combination regimens against aggressive triple-negative breast cancer (TNBC). Alfa Cytology delivers an end-to-end PY8119 xenograft model service, combining fully authenticated cell line assets with standardized inoculation and multi-parametric evaluation protocols to accelerate preclinical oncology drug discovery pipelines.

Overview of PY8119 Xenograft Model for Breast Cancer

The PY8119 model is a highly valuable mouse-derived mammary carcinoma platform widely utilized in preclinical oncology to investigate triple-negative breast cancer (TNBC) progression, tumor microenvironment (TME) dynamics, and metastatic cascades. Originally isolated from a spontaneous mammary tumor in a C57BL/6 female mouse expressing a specific polyoma middle T antigen variant or exhibiting specific lineage alterations, this cell line is characteristically defined by its triple-negative receptor status (lacking ER, PR, and HER2 expression) and a homozygous Tp53 mutation. Unlike human-derived TNBC models that mandate immunodeficient hosts, PY8119 is syngeneic to C57BL/6 mice.

When established in vivo as a xenograft, PY8119 cells develop into poorly differentiated epithelial-mesenchymal tumors that faithfully recapitulate the highly aggressive kinetics, extensive stromal infiltration, and spontaneous macro-metastasis to secondary organs (such as the lungs) observed in clinical TNBC patients. The model exhibits consistent tumor take rates and steady, predictable growth profiles in vivo without requiring exogenous hormonal matrices.

Fig 1. FFPE PY8119 lung sections were stained with TUNEL assay, and the number of apoptotic cells/20 × HPF were counted. (Hsu L, et al., 2025)

Cell Line Information: PY8119

The PY8119 cell line preserves a distinct epithelial-like morphology in vitro and reliably maintains its triple-negative phenotype, Tp53 mutational status, and syngeneic compatibility upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the PY8119 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including TIL immunophenotyping, metastatic lesion assessment, and PK/PD profiling. Leveraging our expertise in syngeneic triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of PY8119 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the PY8119 xenograft model:

• Cell Culture & Quality Control: PY8119 cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory identity profiling and mycoplasma clearance checks to guarantee phenotypic purity and baseline viability before inoculation.
• Host Selection & Acclimatization: Standardized syngeneic C57BL/6 mice or specific humanized mouse strains are selected based on study criteria and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability PY8119 cells is prepared and blended with a verified biological matrix carrier to optimize spatial distribution and support initial engraftment. The mixture is precisely injected in vivo via subcutaneous or orthotopic mammary fat pad routes.
• Longitudinal Growth & Health Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal body weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. PY8119 Xenograft Model Construction Workflow

Case Study - PY8119 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the PY8119 syngeneic xenograft model was successfully utilized to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting the tumor microenvironment in combination with a standardized anti-PD-1 immune checkpoint antibody. Under optimized modeling conditions and precise orthotopic mammary fat pad inoculation protocols, our technical team achieved highly reproducible tumor engraftment and uniform growth curves across all immunocompetent cohorts.

Our Advantages

Choosing the right partner for your aggressive triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified murine tumor cell lines with stable, traceable genetic hallmarks and confirmed syngeneic host compatibility.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance across immunocompetent animal cohorts.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, tumor-infiltrating lymphocyte (TIL) immunophenotyping, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research and animal welfare standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive triple-negative breast cancer or evaluate novel immuno-oncology agents using the robust PY8119 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.